ABSTRACT
@#Timor deer (Cervus timorensis) at Surabaya zoo, Indonesia, that were found to be naturally infected with Fasciola, showed elevated level of serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP). Of a total of 75 deer examined, 12 (25%) of the 47 adult deer and 8 (29%) of the 28 juvenile deer were found to be infected with fascioliasis, as evidenced by the shedding of the parasite eggs. The level of ALT, AST and ALP were significantly elevated (p<0.05) in all the infected deer. Only Fasciolainfected deer showed elevated serum liver enzyme. Deer with elevated enzyme level show a trend that positively correspond with higher Egg per gram of feces (EPG). The average size of the parasite eggs at 169.0±11.1 × 96.0±3.5μm, correspond well with that of Fasciola gigantica. No other trematode eggs were observed besides that of F. gigantica. There was no significant difference in the enzyme profile between the two sexes in both the infected and the uninfected group. This is the first report of the elevation of serum liver enzyme in Timor deer that is associated with not only fascioliasis and also correspond positively with the EPG.
ABSTRACT
BACKGROUND: Oral etretinate treatment is associated with the changes in serum lipid concentration and the elevation of serum liver enzymes. In Korea, chronic degenerative diseases like diabetes and hypertension are increasing and the prevalences of HBsAg and chronic liver diseases are much higher than those in western countries. Therefore these changes in serum lipids and liver enzymes during etretinate treatrment are important in Korea as risk factors for atherosclerosis and aggravation of preexisting liver diseases. OBJECTIVE: We tried to observe the sequential pattern, frequency, severity, and relationship between pretreatment value and posttreatment values in the changes of serum lipids and liver enzymes in patients with psoriasis luring etretinate treatment. METHODS: Fourty-one patients with psoriasis were studied during etretinate treatment with the starting dose of 0.5-1.0mg/kg/day. The levels of serum triglyceride, serum cholesterol, HDL-cholesterol, and sGOT, sGPT was repeatedly determined until the 16th week of etretinate treatment. RESULTS: l. In serum triglyceride and cholesterol, the average of concentrations in each treatment period was usually higher than pretreatment value during the 16 weeks of treatment, but no sequential pattern of changes was observed 2. The number of patients with the maximum of posttreatment values higher than the normal limit were 12(29.3%) in triglyce side, 6(14.6%) in cholesterol, 0 in sGOT, and 5(12.5%) in sGPT. The number of patients with the minimum of posttreatment values lower than the normal limit were 15(36.6%) in HDL-cholesterol. 3. In serum cholesterol, patients with an abnormal pretreatment value are more prone to elevation above the normal limit duriing etretinate treatment than patients with a normal pretreatment value. CONCLUSION: In patients with psoriasis the increases in serum triglyceride, serum cholesterol, sGOT, sGPT and the decrease in HDL-cholesterol were occurred frequently during etretinate treatment. Therefore monitoring of serum lipid concentration and serum liver enzyme levels on a regular basis during etretinate treatment is essential for its safe use in patients with psoriasis, es- pecially in cases of long term etretinate treatment.